Gabapentin & Dementia Risk: New Concerns About Chronic Pain Medication
Gabapentin, an anticonvulsant medication initially approved for seizure disorders and postherpetic neuralgia, has seen a dramatic increase in prescriptions over the last 15 years. This rise coincides with growing concerns about the opioid epidemic and a subsequent shift towards alternative pain management strategies. While often viewed as a safer option than opioids, emerging research suggests potential long-term neurological risks associated with gabapentin use, particularly concerning cognitive decline and dementia.
A Surge in Prescriptions
According to a report from CDC researchers published in in Annals of Internal Medicine, gabapentin prescriptions in the U.S. More than doubled between and . The number of Americans taking the medication nearly tripled during that period, rising from 5.8 million to 15.5 million. By , gabapentin was the fifth most dispensed drug in U.S. Retail pharmacies.
Increased Dementia Risk, Especially in Younger Adults
Recent studies have linked gabapentin prescriptions for chronic low back pain with an increased risk of cognitive impairment and dementia. A study published in in Regional Anesthesia &. Pain Medicine tracked over 52,000 adults over a 10-year period. Researchers found that chronic pain patients with six or more gabapentin prescriptions had a higher incidence of mild cognitive impairment and dementia compared to those not prescribed the medication. Specifically, dementia risk was more than double, and mild cognitive impairment risk was more than triple, among individuals aged years old. Similar patterns were observed in those aged years.
A separate study, based on a retrospective analysis of over 26,000 adults diagnosed with chronic low back pain using the TriNetX national database, reinforced these findings. This research excluded individuals with prior gabapentin use, dementia, epilepsy, stroke, or cancer to isolate the potential effects of the medication. The study demonstrated that the risk of both cognitive impairment and dementia increased with the frequency of gabapentin prescriptions; patients with 12 or more prescriptions were significantly more likely to develop these conditions than those prescribed the drug fewer times.
Prescribing Cascades and Unintended Consequences
Concerns extend beyond dementia risk. A recent analysis in JAMA Network Open highlighted the potential for “prescribing cascades”—where the side effects of one medication are treated with another—related to gabapentinoid-induced edema. Researchers found that clinicians often failed to consider gabapentin’s potential role in fluid retention, instead attributing it to conditions like congestive heart failure or venous stasis, and subsequently prescribing diuretics. This resulted in potential harm for nearly one in four patients.
Global Uncertainty and Monitoring Needs
The lack of clear guidance regarding the initiation, monitoring, and tapering of gabapentinoid use is a global concern. A review of qualitative studies in the European Journal of Pain revealed that clinicians worldwide expressed uncertainty about best practices for gabapentin use.
Gabapentin and Self-Harm Risk
Long-standing concerns about a potential link between gabapentin and self-harm have also been revisited. A U.K. Self-controlled case series published in the BMJ in found that self-harm risk increased both before starting gabapentin treatment and after stopping it, suggesting the importance of careful patient monitoring throughout the course of treatment.
The common side effects of gabapentin include drowsiness, dizziness, blurred or double vision, and difficulty with concentration. While chronic pain is a debilitating condition, it is crucial that medical professionals carefully weigh the potential benefits of gabapentin against its potential risks, and ensure that treatment does not inadvertently create new problems.
As one individual who personally experienced chronic pain and subsequently used gabapentin for approximately two years, I discontinued its use after failing to identify any noticeable benefits, in consultation with my physician. The emerging research underscores the need for a cautious and informed approach to gabapentin prescribing, particularly given the potential for long-term neurological consequences.